CIBC Asset Management Inc Has $45.20 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

CIBC Asset Management Inc lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 229,989 shares of the medical research company's stock after selling 33,763 shares during the quarter. CIBC Asset Management Inc owned 0.13% of IQVIA worth $45,195,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC bought a new stake in IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC raised its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. raised its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Concord Wealth Partners bought a new stake in IQVIA during the third quarter worth $57,000. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $251.22.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company's stock.

IQVIA Price Performance

IQVIA stock traded down $2.51 during trading hours on Thursday, reaching $194.01. 1,081,192 shares of the stock were exchanged, compared to its average volume of 1,402,682. The company has a market cap of $34.16 billion, a P/E ratio of 25.87, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a 50 day moving average of $199.86 and a two-hundred day moving average of $216.95.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts expect that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.